# Effectiveness and Safety of Combination of Nebivolol and Amlodipine in Hypertensive Patients Versus Each Monotherapy

Study · id `cardio:ct-nct05513937` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05513937](<https://clinicaltrials.gov/study/NCT05513937>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05513937

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 301 participants.

## Technical summary

Registry record NCT05513937. Non-randomized; no masking; primary purpose treatment. Start 2022-05-12 (actual); primary completion 2022-11-15 (actual). Results posted on 2025-02-04.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 301 participants (enrolled count; ClinicalTrials.gov record NCT05513937, source copy `cardio:ctgov-nct05513937-2025-02-04`, retrieved 2026-10-26)
- Started: 2022-05-12 (actual) (ClinicalTrials.gov record NCT05513937, source copy `cardio:ctgov-nct05513937-2025-02-04`, retrieved 2026-10-26)
- Primary completion: 2022-11-15 (actual) (ClinicalTrials.gov record NCT05513937, source copy `cardio:ctgov-nct05513937-2025-02-04`, retrieved 2026-10-26)
- Completion: 2022-11-15 (actual) (ClinicalTrials.gov record NCT05513937, source copy `cardio:ctgov-nct05513937-2025-02-04`, retrieved 2026-10-26)
- Results first posted: 2025-02-04 (ClinicalTrials.gov record NCT05513937, source copy `cardio:ctgov-nct05513937-2025-02-04`, retrieved 2026-10-26)
- Countries: Bulgaria (ClinicalTrials.gov record NCT05513937, source copy `cardio:ctgov-nct05513937-2025-02-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05513937-2025-02-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effectiveness and Safety of Combination of Nebivolol and Amlodipine in Hypertensive Patients Versus Each Monotherapy
- Acronym: Botticelli
- Condition: Hypertension
- Intervention (Drug): Nebivolol
- Intervention (Drug): Amlodipine
- Lead sponsor: Menarini International Operations Luxembourg SA
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Nebivolol (`cardio:nebivolol`)
- Registry intervention name matches this record: Amlodipine (`cardio:amlodipine`)
- Registry lists this organization as the lead sponsor: Menarini International Operations Luxembourg SA (`cardio:org-menarini-international-operations-luxembourg-sa`)

## Provenance

Content hash: f0754d0cb5dec2e908bd19a5c8bdad82ea6abf555de33c40faf60fc0026cd66d
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
